Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population.
BACKGROUND
The tumor suppressor TP53 and its negative regulator MDM2 play crucial roles in carcinogenesis. Previous case-control studies also revealed TP53 72Arg>Pro and MDM2 309T>G polymorphisms contribute to the risk of common cancers. However, the relationship between these two functional polymorphisms and nasopharyngeal carcinoma (NPC) susceptibility has not been explored.


METHODS
In this study, we performed a case-control study between 522 NPC patients and 722 healthy controls in a Chinese population by using PCR-RFLP.


RESULTS
We found an increased NPC risk associated with the MDM2 GG (odds ratio [OR] = 2.83, 95% confidence interval [CI] = 2.08-3.96) and TG (OR = 1.49, 95% CI = 1.16-2.06) genotypes. An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.22, 95% CI = 1.58-3.10) compared to the Arg/Arg genotype. The gene-gene interaction of MDM2 and TP53 polymorphisms increased adult NPC risk in a more than multiplicative manner (OR for the presence of both MDM2 GG and TP53 Pro/Pro genotypes = 7.75, 95% CI = 3.53-17.58).


CONCLUSIONS
The findings suggest that polymorphisms of MDM2 and TP53 genes may be genetic modifier for developing NPC.
Xiao
Mang
M
Department of Otolaryngology-Head and Neck Surgery, The second affected hospital to Nanchang University, Nanchang, China.
Zhang
Lei
L
Zhu
Xinhua
X
Huang
Jun
J
Jiang
Huifen
H
Hu
Sunhong
S
Liu
Yuehui
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D005260:Female; D016158:Genes, p53; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D051736:Proto-Oncogene Proteins c-mdm2 / Q000096:biosynthesis / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics; D055815:Young Adult
D012333:RNA, Messenger; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2
Nat Genet. 2003 Mar;33(3):357-65
12567188
Cell. 2004 Nov 24;119(5):591-602
15550242
Nucleic Acids Res. 1990 Aug 25;18(16):4961
1975675
Mol Cell Biol. 1999 Feb;19(2):1092-100
9891044
Clin Cancer Res. 2007 May 1;13(9):2627-33
17473193
Carcinogenesis. 2007 Sep;28(9):1996-2001
17638920
Hum Genet. 1994 Jun;93(6):620-4
8005584
Int J Cancer. 2009 Oct 1;125(7):1735-8
19521985
Arch Med Res. 2009 May;40(4):299-305
19608020
Science. 1990 Nov 30;250(4985):1233-8
1978757
Nature. 1992 Mar 19;356(6366):215-21
1552940
J Clin Oncol. 2008 May 10;26(14):2252-7
18467716
Hum Mutat. 2002 Jun;19(6):607-14
12007217
Nucleic Acids Res. 1998 Aug 1;26(15):3453-9
9671804
Cancer Lett. 2008 Mar 8;261(1):21-5
18248785
Blood. 1995 Mar 15;85(6):1580-9
7888675
Carcinogenesis. 2002 Mar;23(3):381-7
11895852
Cancer Res. 1999 Jan 1;59(1):1-7
9892174
BMC Cancer. 2008 Apr 23;8:116
18433491
Cancer Genet Cytogenet. 1993 Apr;66(2):83-92
8500106
Nucleic Acids Res. 2001 Sep 1;29(17):E88-8
11522844
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2717-23
18086778
Methods. 2001 Dec;25(4):409-18
11846610
Carcinogenesis. 2008 Nov;29(11):2120-5
18701437
Eur J Cancer. 2008 Mar;44(5):760-6
18313915
Leuk Res. 2009 Nov;33(11):1454-8
19423162
Cancer Res. 2007 Jun 15;67(12):5831-9
17575151
Hum Mutat. 2006 Jan;27(1):110-7
16287156
Cancer Res. 2005 Oct 15;65(20):9582-7
16230424
Blood. 1991 Mar 15;77(6):1153-6
1705829
Nat Rev Cancer. 2002 Aug;2(8):594-604
12154352
Cell. 2009 May 15;137(4):609-22
19450511